PMID- 14559319
OWN - NLM
STAT- MEDLINE
DCOM- 20040323
LR  - 20190917
IS  - 0899-9007 (Print)
IS  - 0899-9007 (Linking)
VI  - 19
IP  - 10
DP  - 2003 Oct
TI  - Soluble tumor necrosis factor-alpha receptor type 1 during selenium 
      supplementation in psoriasis patients.
PG  - 847-50
AB  - OBJECTIVE: Tumor necrosis factor-alpha (TNF-alpha) and its receptors play 
      important roles in the induction and maintenance of psoriatic lesions. Selenium 
      (Se), a trace element with immunomodulatory properties, is usually decreased in 
      psoriasis patients. We examined the influence of Se supplementation on soluble 
      TNF-alpha receptor type 1 (sTNF-R1) and topical treatment in psoriasis patients. 
      METHODS: The study was conducted in between January and June 2002. Twenty-two 
      inpatients with active plaque psoriasis received topical treatment with 5% 
      salicylic acid ointment, 0.1% to 0.3% dithranol ointment, and 200 microg daily of 
      Se as selenomethionine (SeMet; n = 11, group 1) or placebo (n = 11, group 2) for 
      4 wk. Psoriasis Area and Severity Index (PASI) score and Se and sTNF-R1 
      concentrations were assessed at baseline and every 2 wk. Control sera were 
      obtained from 10 healthy subjects. For statistical analysis, parametric tests 
      were used, and the level of significance was set at P = 0.05. RESULTS: The 
      baseline sTNF-R1 levels were 1.87 +/- 0.58 ng/mL (1.98 +/- 0.44 ng/mL in group 1 
      and 1.75 +/- 0.69 ng/mL in group 2, P = 0.34) in psoriasis patients and 1.65 +/- 
      0.25 ng/mL in control subjects (P = 0.17); baseline Se concentrations were 48.31 
      +/- 13.20 microg/L (48.31 +/- 13.20 microg/L in group 1 and 50.35 +/- 13.49 
      microg/L in group 2, P = 0.41) in psoriasis patients and 58.30 +/- 17.21 microg/L 
      in control subjects (P = 0.05). A positive correlation between PASI and sTNF-R1 
      was noticed (r = 0.36, P = 0.04; r = 0.51 in group 1 and r = 0.18 in group 2). 
      After 4 wk, almost complete remission of skin lesions was achieved in both 
      groups, but the PASI score was higher in group 1 than in group 2 (4.30 +/- 3.92 
      and 1.67 +/- 1.17, respectively; P < 0.05). TNF-R1 levels were 1.81 +/- 0.42 
      ng/mL in group 1 and 1.33 +/- 0.40 ng/mL in group 2 (P = 0.01), and the 
      correlation between PASI score and TNF-R1 level became inverse (r = -0.24 in 
      group 1 and r = -0.59 in group 2). Se concentrations were 107.51 +/- 18.08 
      microg/L in group 1 and 56.83 +/- 15.32 microg/L in group 2 (P < 0.01). 
      CONCLUSIONS: Increased level of sTNF-R1 may be an indicator of active psoriasis. 
      Supplementation with selenomethionine was ineffective as adjuvant treatment in 
      plaque psoriasis and may contribute to the maintenance of elevated TNF-R1 
      concentration in psoriasis patients despite the remission of skin lesions.
FAU - Serwin, Agnieszka B
AU  - Serwin AB
AD  - Department of Dermatology and Venereology, Medical University of Bialystok, 
      Bialystok, Poland. agabser@amb.edu.pl
FAU - Mysliwiec, Hanna
AU  - Mysliwiec H
FAU - Hukalowicz, Katarzyna
AU  - Hukalowicz K
FAU - Porebski, Piotr
AU  - Porebski P
FAU - Borawska, Maria
AU  - Borawska M
FAU - Chodynicka, Bozena
AU  - Chodynicka B
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Nutrition
JT  - Nutrition (Burbank, Los Angeles County, Calif.)
JID - 8802712
RN  - 0 (Anti-Infective Agents)
RN  - 0 (Biomarkers)
RN  - 0 (Keratolytic Agents)
RN  - 0 (Receptors, Tumor Necrosis Factor)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - H6241UJ22B (Selenium)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - U8CJK0JH5M (Anthralin)
SB  - IM
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - Anthralin/therapeutic use
MH  - Anti-Infective Agents/therapeutic use
MH  - Biomarkers/blood
MH  - Dietary Supplements
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Keratolytic Agents/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Psoriasis/*blood/*drug therapy/pathology
MH  - Receptors, Tumor Necrosis Factor/*metabolism
MH  - Salicylic Acid/therapeutic use
MH  - Selenium/*administration & dosage/therapeutic use
MH  - Solubility
MH  - Tumor Necrosis Factor-alpha/*metabolism
EDAT- 2003/10/16 05:00
MHDA- 2004/03/24 05:00
CRDT- 2003/10/16 05:00
PHST- 2003/10/16 05:00 [pubmed]
PHST- 2004/03/24 05:00 [medline]
PHST- 2003/10/16 05:00 [entrez]
AID - S0899900703001655 [pii]
AID - 10.1016/s0899-9007(03)00165-5 [doi]
PST - ppublish
SO  - Nutrition. 2003 Oct;19(10):847-50. doi: 10.1016/s0899-9007(03)00165-5.